Casopitant
Lua error in Module:Infobox at line 314: malformed pattern (missing ']').
Casopitant (trade names Rezonic (US), Zunrisa (EU)) is an neurokinin 1 (NK1) receptor antagonist undergoing research for the treatment of chemotherapy-induced nausea and vomiting (CINV).[1] It is currently under development by GlaxoSmithKline (GSK).
In July 2008, the company filed a marketing authorisation application with the European Medicines Agency. The application was withdrawn in September 2009 because GSK decided that further safety assessment was necessary.[2]
See also
<templatestyles src="Div col/styles.css"/>
References
<templatestyles src="Reflist/styles.css" />
Cite error: Invalid <references> tag; parameter "group" is allowed only.
<references />, or <references group="..." />- REDIRECT Template:Peptide receptor modulators
<templatestyles src="Asbox/styles.css"></templatestyles>
 |
This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it. |
<templatestyles src="Asbox/styles.css"></templatestyles>
 |
This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |
- Pages with reference errors
- Infobox drug articles without a structure image
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Drugs with no legal status
- Pages using div col with unknown parameters
- Antiemetics
- NK1 receptor antagonists
- Amides
- Piperazines
- Piperidines
- Organofluorides
- Gastrointestinal system drug stubs
- Nervous system drug stubs
